Library Item - Page 35 of 792 Posts on Medivizor
Navigation Menu

Library Item Posts on Medivizor

Evaluating the predictors of early recurrence in patients with stage IIIA-N2 non-small cell lung cancer after surgery.

Evaluating the predictors of early recurrence in patients with stage IIIA-N2 non-small cell lung cancer after surgery.

Posted by on Jan 20, 2022 in Lung cancer | 0 comments

In a nutshell This study evaluated the predictors of early recurrence in patients with stage IIIA-N2 non-small cell lung cancer (NSCLC) after surgery. The data showed that early recurrence after surgery was associated with poor survival outcomes in patients with stage IIIA-N2 NSCLC. Smoking history, large tumor size, increased lymph node ratio, and...

Read More

How beneficial is sodium-glucose co-transporter 2 inhibitor treatment for patients with type 2 diabetes mellitus and heart failure?

How beneficial is sodium-glucose co-transporter 2 inhibitor treatment for patients with type 2 diabetes mellitus and heart failure?

Posted by on Jan 20, 2022 in Diabetes mellitus | 0 comments

In a nutshell This study reviewed the long-term use of sodium-glucose co-transporter 2 inhibitors (SGLT-2i) on the risk of mortality and hospitalization for heart failure (HHF) in patients with type 2 diabetes (T2D) and heart failure (HF). The authors concluded that long-term use of SGLT-2 inhibitors can help to reduce mortality risk and HHF in...

Read More

Evaluating the effectiveness and safety of docetaxel given every 2 weeks plus androgen deprivation therapy in patients with metastatic castration-naïve prostate cancer.

Evaluating the effectiveness and safety of docetaxel given every 2 weeks plus androgen deprivation therapy in patients with metastatic castration-naïve prostate cancer.

Posted by on Jan 19, 2022 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of docetaxel (Taxotere) given every 2 weeks plus androgen-deprivation therapy (ADT) in patients with metastatic castration-naïve prostate cancer (mCNPC). The data showed that docetaxel given every 2 weeks plus ADT was safe and effective in these patients. Some background MCNPC...

Read More

Comparing response to SARS-CoV-2 mRNA vaccine doses for patients with RA and healthy controls.

Comparing response to SARS-CoV-2 mRNA vaccine doses for patients with RA and healthy controls.

Posted by on Jan 19, 2022 in Rheumatoid Arthritis | 0 comments

In a nutshell This study evaluated immune responses after two doses of SARS-CoV-2 messenger RNA (mRNA) vaccines in patients with inflammatory joint diseases including rheumatoid arthritis (RA) compared to healthy controls (HCs). The data showed that patients with inflammatory joint diseases had similar responses to mRNA vaccines after 2...

Read More

Updated NCCN guidelines for acute lymphoblastic leukemia.

Updated NCCN guidelines for acute lymphoblastic leukemia.

Posted by on Jan 16, 2022 in Leukemia | 0 comments

In a nutshell These guidelines aimed to update treatment options for patients with Philadelphia chromosome-positive (Ph+) and negative (Ph-) acute lymphoblastic leukemia (ALL). Some background Acute lymphoblastic leukemia (ALL) represents 75% to 80% of acute leukemia among children and so is the most common form of childhood leukemia. It represents...

Read More

Comparing tibial nerve stimulation and antimuscarinic agents for the treatment of overactive bladder syndrome.

Comparing tibial nerve stimulation and antimuscarinic agents for the treatment of overactive bladder syndrome.

Posted by on Jan 16, 2022 in Overactive bladder | 0 comments

In a nutshell This study compared the effectiveness and safety of tibial nerve stimulation (TNS) versus antimuscarinic agents for the treatment of patients with overactive bladder (OAB). The study found that TNS was safer and as effective as antimuscarinic agents for the treatment of OAB. Some background Overactive bladder (OAB) occurs when the...

Read More

Do combination therapies given in fixed-doses polypills with aspirin reduce the risk of cardiovascular disease events?

Do combination therapies given in fixed-doses polypills with aspirin reduce the risk of cardiovascular disease events?

Posted by on Jan 16, 2022 in Hypertension | 0 comments

In a nutshell This study investigated whether a combination pill given in fixed doses with or without aspirin can reduce the risk of cardiovascular disease events in patients without a previous history of cardiovascular disease. The data showed that a fixed-dose combination treatment strategy with aspirin significantly reduced the risks of...

Read More

Comparing the effectiveness and safety of first-line treatment options in patients with advanced ALK-rearranged NSCLC.

Comparing the effectiveness and safety of first-line treatment options in patients with advanced ALK-rearranged NSCLC.

Posted by on Jan 16, 2022 in Lung cancer | 0 comments

In a nutshell This study compared the effectiveness and safety of first-line treatment options in patients with advanced ALK-rearranged non-small-cell lung cancer (NSCLC). The data showed that alectinib (Alecensa) and lorlatinib (Lorbrena) were the most effective and safest first-line treatment options for these patients. Some background...

Read More

Evaluating the effectiveness of adding immunotherapy to chemotherapy for metastatic triple-negative breast cancer.

Evaluating the effectiveness of adding immunotherapy to chemotherapy for metastatic triple-negative breast cancer.

Posted by on Jan 9, 2022 in Breast cancer | 0 comments

In a nutshell This study compared the effectiveness of adding immunotherapy (IT) to chemotherapy (CT) for the treatment of patients with metastatic triple-negative breast cancer (TNBC). The data showed that the addition of IT to CT significantly improved survival without cancer worsening. However, IT plus CT combination did not...

Read More

Comparing the effectiveness of PARP inhibitors for the treatment of patients with BRCA1 and BRCA2 mutations.

Comparing the effectiveness of PARP inhibitors for the treatment of patients with BRCA1 and BRCA2 mutations.

Posted by on Jan 9, 2022 in Prostate cancer | 0 comments

In a nutshell This study compared the effectiveness of PARP inhibitors for the treatment of patients with BRCA1 and BRCA2 mutations in solid tumors. The data showed that PARP inhibitors could benefit both patients with BRCA1 and BRCA2 mutations with similar effectiveness. Some background BRCA1 and BRCA2 gene mutations (abnormalities) can be found in...

Read More

Comparing the effectiveness of PARP inhibitors for the treatment of patients with BRCA1 and BRCA2 mutations.

Comparing the effectiveness of PARP inhibitors for the treatment of patients with BRCA1 and BRCA2 mutations.

Posted by on Jan 9, 2022 in Breast cancer | 0 comments

In a nutshell This study compared the effectiveness of PARP inhibitors for the treatment of patients with BRCA1 and BRCA2 mutations in solid tumors. The data showed that PARP inhibitors could benefit both patients with BRCA1 and BRCA2 mutations with similar effectiveness. Some background BRCA1 and BRCA2 gene mutations (abnormalities)...

Read More

Evaluating the effectiveness and safety of maintenance strategies after first-line treatment with anti-EGFR plus doublet chemotherapy regimen in real-world patients with left-sided RAS/BRAF wild-type metastatic colorectal cancer.

Evaluating the effectiveness and safety of maintenance strategies after first-line treatment with anti-EGFR plus doublet chemotherapy regimen in real-world patients with left-sided RAS/BRAF wild-type metastatic colorectal cancer.

Posted by on Jan 9, 2022 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of maintenance strategies after first-line treatment with anti-EGFR (epidermal growth factor receptor) plus doublet chemotherapy regimen in real-world patients with left-sided RAS/BRAF wild-type metastatic colorectal cancer (mCRC). The data showed that maintenance therapy with 5-fluorouracil...

Read More